Table 5.
Selected active trials of additional CD3 x BCMA targeting bispecific antibodies in multiple myeloma (MM).
| Trial ID (References) | Drugs | Phase | Enrollment (N) | Trial Title |
|---|---|---|---|---|
| NCT05650632 | ABBV-383 | I | 80 | Multicenter, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with RRMM |
| NCT05259839 [124] | ABBV-383 + various antimyeloma agents | I | 270 | Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with RRMM |
| NCT04735575 | EMB-06 | I/II | 66 | First-in-human, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients with RRMM |
| NCT03486067 [125] | Alnuctamab (CC-93269) | I | 220 | Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects with RRMM |
| NCT05828511 | Linvo (REGN5458) | I/II | 132 | Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic MM |
| NCT05730036 | Elo+ Pom + Dex +/− | III | 286 | Open-label, Randomized Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients with RRMM (LINKER-MM3) |
| NCT05137054 | Linvo + various anti-myeloma agents | Ib | 317 | Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients with RRMM |
| NCT03761108 [126,127,128] | Linvo | I/II | 309 | FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with RRMM |
| NCT04083534 [118] | REGN5459 | I/II | 43 | FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with RRMM |
| NCT03933735 [129] | TNB-383B | I/II | 220 | Multicenter Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with RRMM |
| NCT05646758 | TQB2934 | I | 140 | Clinical Trial Evaluating the Tolerance and Pharmacokinetics of TQB2934 for Injection in MM Subjects |
| NCT04123418 [123] | WVT078 | I | 56 | Open-label, Multicenter, Study of WVT078 in Subjects with RRMM |
| NCT04184050 [130] | HPN217 | I | 70 | Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with RRMM |
Dex = dexamethasone; Elo = elotuzumab; FIH = first in humans; Linvo = linvoseltamab; MM = multiple myeloma; Pom = pomalidomide; RRMM = relapsed and/or refractory MM.